| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000020891 |
| Receipt No. | R000024102 |
| Scientific Title | Phase II study of VAC1.2(vincristine, actinomycin-D, cyclophosphamide) followed by VA for patients with newly diagnosed low-risk subset A rhabdomyosarcoma |
| Date of disclosure of the study information | 2016/03/01 |
| Last modified on | 2020/08/08 (Ver. 6) |
| Basic information | ||
| Public title | Phase II study of VAC1.2(vincristine, actinomycin-D, cyclophosphamide) followed by VA for patients with newly diagnosed low-risk subset A rhabdomyosarcoma | |
| Acronym | Phase II study of VAC1.2/VA therapy for patients with newly diagnosed low-risk subset A rhabdomyosarcoma | |
| Scientific Title | Phase II study of VAC1.2(vincristine, actinomycin-D, cyclophosphamide) followed by VA for patients with newly diagnosed low-risk subset A rhabdomyosarcoma | |
| Scientific Title:Acronym | Phase II study of VAC1.2/VA therapy for patients with newly diagnosed low-risk subset A rhabdomyosarcoma | |
| Region |
|
|
| Condition | |||||||||||||
| Condition | rhabdomyosarcoma | ||||||||||||
| Classification by specialty |
|
||||||||||||
| Classification by malignancy | Malignancy | ||||||||||||
| Genomic information | NO | ||||||||||||
| Objectives | |
| Narrative objectives1 | Determine the safety and efficacy of four cycles of VAC1.2(vincristine, actinomycin-D and cyclophosphamide 1.2 g/m2) followed by four cycles of VA for patients with low-risk subset A rhabdomyosarcoma(embryonal rhabdomyosarcoma, Stage 1, Clinical Group I/II or orbital Clinical Group III N0, Nx, or Stage 2, Clinical Group I/II) |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | event free survival |
| Key secondary outcomes | overall survival
time to treatment failure overall response rate frequency and grade of adverse event diagnostic and prognostic significance of serum miR-206 value quality control of radiation therapy |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | chemotherapy
VAC1.2 VA surgery radiation therapy |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Histologically confirmed newly diagnosed embryonal rhabdomyosarcoma(RMS), meeting criteria for low-risk subset A.
2) Age younger than 30 years old. 3) Initiation of chemotherapy within 42 days after first surgery. 4) No prior history of malignancy. 5) ECOG 0-2 (>= 16 years old) or Lansky 50-100% (< 16 years old) 6) Patients must have sufficient organ function. 7) All patients and/ or their parents or legal guardians must sign a written imformed consent. |
|||
| Key exclusion criteria | 1) Patients with central nervus system primary or metastatic tumors
2) Patients with synchronous or metachrounous concomitant malignancies 3) Patients with Charcot-Marie-Tooth disease or varicella 4) Patients with uncontrollable complications Interstitial pneumonia, pulmonary fibrosis, severe emphysema Uncontrollable diabetes mellitus Uncontrollable hypertension Severe electrocardiogram abnormality or clinically significant heart disease(heart failure, myocardial infarction, angina pectoris) Liver failure, cirrhosis Renal failure 5) Patients with contraindication of drugs used in this study 6) Female patints who are pregnant or breastfeeding mother or patients considering pregnancy 7) Patients with any other inappropriate conditon judged by physician |
|||
| Target sample size | 22 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Graduate School of Medical Science, Kyoto Prefectural University of Medicine | ||||||
| Division name | Department of Pediatrics | ||||||
| Zip code | 602-8566 | ||||||
| Address | 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto | ||||||
| TEL | 075-251-5571 | ||||||
| tsuchiya@koto.kpu-m.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Graduate School of Medical Science, Kyoto Prefectural University of Medicine | ||||||
| Division name | Department of Pediatrics | ||||||
| Zip code | 602-8566 | ||||||
| Address | 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto | ||||||
| TEL | 075-251-5571 | ||||||
| Homepage URL | |||||||
| tsuchiya@koto.kpu-m.ac.jp | |||||||
| Sponsor | |
| Institute | Japan Rhabdomyosarcoma Study Group |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Grant for innovative clinical cancer research from the Ministry of Health, Labour, and Welfare |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Kyoto Prefectural University of Medicine, Clinical Research R eview Board |
| Address | 465 Kajii-cho, Kawamachi-Hirokoji, Kamig yo-ku, Kyoto, JAP AN, Kyoto |
| Tel | 075-251-5337 |
| rinri@koto.kpu-m.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000024102 |